|Articles|May 22, 2023

Infectious Disease Pharmacists Day 2023: Our Top Stories

Today, we celebrate the crucial role of infectious disease pharmacists in combating infectious diseases and promoting patient safety.

Today, May 22, is the third annual National Infectious Disease Pharmacists Day. This day was designated to honor the remarkable efforts of infectious disease pharmacists across the country.

These specialized pharmacists work collaboratively with healthcare teams to develop treatment plans, monitor drug interactions, and provide valuable insights on emerging and challenging infectious diseases. Contagion acknowledges their significant contributions to patient care and public health with our top 5 stories by and for infectious disease pharmacists.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Related to this article

November 8th, 2026

IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures

IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.

November 8th, 2026

A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia

IDSA and ESCMID released 7 consensus statements to assist in managing individuals with Staphylococcus aureus Bacteremia (SAB). This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline.

November 7th, 2026

Carbapenem-Sparing Therapy for ESBL Bacteremia: New Trials, Old Questions

New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.

November 6th, 2026

Recent Guideline Updates in the Management of Urinary Tract Infections

Recent urinary tract infection guideline updates from multiple international medical societies highlight evolving recommendations, including a major shift in classification, moving from anatomy- and risk factor–based definitions toward distinguishing localized from systemic infections.

November 1st, 2026

Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics

In a national survey of 959 US adults, 27.9% said they had exaggerated or made up symptoms to obtain antibiotics, most often cold-like symptoms, with implications for outpatient stewardship.

October 30th, 2026

Thinking Outside the IV: Implementation of a COpAT Program for Patients With Bone and Joint Infections

An APP-driven complex outpatient antimicrobial therapy (COpAT) program for patients with bone and joint infections cut mean time to post-discharge follow-up from 20.1 to 9.7 days but did not significantly reduce 30-day readmissions or emergency department visits.

October 28th, 2026

AI-Designed Phage Treatment of Resistant Bacterial Infection

Company announces first AI-designed personalized phage treatment for antibiotic-resistant bacterial infection in human patient.

Alisse Hannaford, MD (Image Credit: Mass General)

October 24th, 2026

Early Antibiotic Stop in Neutropenic Fever Did Not Raise Severe Events

Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.

Infectious Disease Pharmacists Day 2023: Our Top Stories

Related to this article

Trending on Contagion Live

Ebola Update: DRC Outbreak Tops 10,000 Cases as Kenya, Nigeria Report Spread

Is the mRNA Influenza Vaccine More Efficacious in Older Adults?

Elebsiran and Tobevibart Meet Primary End Point in Hepatitis Delta Study